6303-46-4

Basic information

• Product Name: 6-chloro-N-(3,4-dichlorophenyl)pyrimidin-4-amine
• CAS NO: 6303-46-4
• Molecular Formula: C₁₀H₆Cl₃N₃
• Molecular Weight: 274.5337
• Mol File: 6303-46-4.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 400.4°C at 760 mmHg
• Flash Point: 195.9°C
• Density: 1.544g/cm³
• Vapor Pressure: 1.28E-06mmHg at 25°C
• Refractive Index: 1.671
• CAS DataBase Reference: 6-chloro-N-(3,4-dichlorophenyl)pyrimidin-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chloro-N-(3,4-dichlorophenyl)pyrimidin-4-amine(6303-46-4)
• EPA Substance Registry System: 6-chloro-N-(3,4-dichlorophenyl)pyrimidin-4-amine(6303-46-4)

Safety Data

• Hazardous Substances Data: 6303-46-4(Hazardous Substances Data)

Usage

General Description

6-chloro-N-(3,4-dichlorophenyl)pyrimidin-4-amine is a chemical compound with the molecular formula C10H6Cl3N3. It is a pyrimidine derivative with two chlorine atoms attached to the phenyl group. 6-chloro-N-(3,4-dichlorophenyl)pyrimidin-4-amine has potential applications in a variety of fields including pharmaceuticals, agrochemicals, and materials science. Its precise chemical properties and potential uses will depend on its specific applications and the context in which it is being utilized. Further research and testing will be necessary to fully understand the potential benefits and risks associated with this compound.

Upstream product

• 1193-21-1 4,6-dichloropyrimidine 
• 95-76-1 m,p-dichloroaniline 

Downstream Products

• 1228298-37-0 3-[6-(3,4-dichlorophenylamino)pyrimidin-4-yl]-benzoic acid methyl ester 
• 1228298-38-1 2-[6-(3,4-dichlorophenylamino)pyrimidin-4-yl]-benzamide 

Relevant articles and documents

Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntingtons disease

We report on the development of a series of pyrimidine carboxylic acids that are potent and selective inhibitors of kynurenine monooxygenase and competitive for kynurenine. We describe the SAR for this novel series and report on their inhibition of KMO activity in biochemical and cellular assays and their selectivity against other kynurenine pathway enzymes. We describe the optimization process that led to the identification of a program lead compound with a suitable ADME/PK profile for therapeutic development. We demonstrate that systemic inhibition of KMO in vivo with this lead compound provides pharmacodynamic evidence for modulation of kynurenine pathway metabolites both in the periphery and in the central nervous system.

Binding or bending: Distinction of allosteric abl kinase agonists from antagonists by an NMR-based conformational assay

Allosteric inhibitors of Bcr-Abl have emerged as a novel therapeutic option for the treatment of CML. Using fragment-based screening, a search for novel Abl inhibitors that bind to the myristate pocket was carried out. Here we show that not all myristate ligands are functional inhibitors, but that the conformational state of C-terminal helix-I is a structural determinant for functional activity. We present an NMR-based conformational assay to monitor the conformation of this crucial helix-I and show that myristate ligands that bend helix-I are functional antagonists, whereas ligands that bind to the myristate pocket but do not induce this conformational change are kinase agonists. Activation of c-Abl by allosteric agonists has been confirmed in a biochemical assay.